ActivMed Practices Research LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,244,527	71
2024	Research	$1,492,098	78
2023	Research	$1,957,093	104
2022	Research	$672,199	56
2021	Research	$490,230	25

Breakdown

Who paid Research payments · program years 2021–2025

Pfizer Inc. $5,806,734 309 payments
Moderna TX, Inc. $48,514 24 payments
GlaxoSmithKline, LLC. $900 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $3,224,850 88 payments
A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,296,429 86 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $465,802 59 payments
A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $323,882 11 payments
A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Covid19 Vaccine and A Recombinant Influenza Vaccine Administered As A Single Injection in Healthy Adults 50 Years of Age Or Older $187,102 12 payments
A 26Week Phase 2B 2Part Randomized Doubleblind Placebo Controlled Parallel Group Doseranging Study to Evaluate the Efficacy and Safety of Pf06882961 Administration in Adults With Obesity $161,479 23 payments
A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $70,052 13 payments
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $48,514 24 payments
A Phase 23 Randomized Doubleblind Placebocontrolled Parallelgroup Study With Lotiglipron Pf07081532 to Assess Cardiovascular and Other Longterm Outcomes in Adults With Type 2 Diabetes Mellitus $22,000 1 payment
A Phase 3 Randomized Doubleblind Placebocontrolled Clinical Study Evaluating the Safety Tolerability Immunogenicity and Efficacy of A Variantadapted Bnt162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age $18,330 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.